Donafenib and immunotherapy before surgery for advanced thyroid cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a combination of two drugs—donafenib (a targeted therapy) and an immunotherapy (anti-PD-1 antibody)—given before surgery for locally advanced differentiated thyroid cancer. The goal is to shrink the tumor to make surgery easier and more complete. If you have this type of thyroid cancer that is hard to remove completely with surgery alone, this study may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of thyroid cancer called differentiated thyroid cancer that is locally advanced (spread beyond the thyroid into nearby tissues like the throat, windpipe, or important blood vessels).
- You are between 18 and 80 years old.
- You have not had any prior cancer treatment for this condition.
- You are willing to have a biopsy of your tumor and to undergo the study procedures.
- Your overall health is good enough to handle the treatment (doctor's assessment score of 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug (a RET inhibitor) taken before surgery to help shrink thyroid cancer that has a specific genetic change (RET alteration). It may make surgery easier or more successful.
This study tests whether giving treatment before surgery (neoadjuvant therapy) helps people with locally advanced thyroid cancer. It aims to shrink the tumor so surgery can be more successful.
This trial tests a new way to choose chemotherapy for thyroid cancer by growing a 'mini-tumor' (organoid) from your biopsy and testing different drugs on it. The goal is to find the drug that is most likely to shrink your cancer.
This trial tests a combination of two oral and infused drugs to slow or shrink advanced thyroid cancer that has stopped responding to initial treatment. It may offer a new option for people with limited choices.
This trial tests two oral medications, avutometinib and defactinib, for people with advanced thyroid cancer that has specific genetic changes. The goal is to see if these drugs can shrink tumors or slow their growth.
This trial tests a combination of two drugs, sinibolimab (an immunotherapy) and lenvatinib (a targeted therapy), given before surgery to shrink locally advanced thyroid cancer that cannot be fully removed. The goal is to make the tumor removable and improve outcomes.
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.